Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham P Cook

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|August 12, 2022
TGFβ limits Myc-dependent TCR-induced metabolic reprogramming in CD8<sup>+</sup> T cellsHelen Carrasco Hope, Gabriella Pickersgill, Pierpaolo Ginefra, et al.
Frontiers in Immunology|April 29, 2026
Phospho-enol pyruvate carboxykinase inhibition limits effector function in inflammatory T cellsRebecca J Brownlie, Helen Carrasco Hope, David Wright, et al.
Blood|July 25, 2013
Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuriaYasser M El-Sherbiny, Richard J Kelly, Anita Hill, et al.
Virology|June 21, 2005
Differential expression of LFA-3, Fas and MHC Class I on Ad5- and Ad12-transformed human cells and their susceptibility to lymphokine-activated killer (LAK) cellsGraham Bottley, Graham P Cook, Josephine L Meade, et al.
Frontiers in Cell and Developmental Biology|May 4, 2023
Pro- and anti-tumour activities of CD146/MCAM in breast cancer result from its heterogeneous expression and association with epithelial to mesenchymal transitionAarren J Mannion, Adam F Odell, Syed Murtuza Baker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2010
A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cellsTim D Holmes, Yasser M El-Sherbiny, Adam Davison, et al.
Iscience|June 18, 2021
Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejectionLynette Steele, Aarren J Mannion, Gary Shaw, et al.
FEBS Letters|March 6, 2007
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cellsSara E Perry, Philip Robinson, Alan Melcher, et al.
Blood|January 18, 2006
A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activityJosephine L Meade, Erika A de Wynter, Peter Brett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2010
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trialHenrik Schmidt, Janet Brown, Ulrik Mouritzen, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|August 12, 2022
TGFβ limits Myc-dependent TCR-induced metabolic reprogramming in CD8<sup>+</sup> T cellsHelen Carrasco Hope, Gabriella Pickersgill, Pierpaolo Ginefra, et al.
Frontiers in Immunology|April 29, 2026
Phospho-enol pyruvate carboxykinase inhibition limits effector function in inflammatory T cellsRebecca J Brownlie, Helen Carrasco Hope, David Wright, et al.
Blood|July 25, 2013
Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuriaYasser M El-Sherbiny, Richard J Kelly, Anita Hill, et al.
Virology|June 21, 2005
Differential expression of LFA-3, Fas and MHC Class I on Ad5- and Ad12-transformed human cells and their susceptibility to lymphokine-activated killer (LAK) cellsGraham Bottley, Graham P Cook, Josephine L Meade, et al.
Frontiers in Cell and Developmental Biology|May 4, 2023
Pro- and anti-tumour activities of CD146/MCAM in breast cancer result from its heterogeneous expression and association with epithelial to mesenchymal transitionAarren J Mannion, Adam F Odell, Syed Murtuza Baker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2010
A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cellsTim D Holmes, Yasser M El-Sherbiny, Adam Davison, et al.
Iscience|June 18, 2021
Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejectionLynette Steele, Aarren J Mannion, Gary Shaw, et al.
FEBS Letters|March 6, 2007
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cellsSara E Perry, Philip Robinson, Alan Melcher, et al.
Blood|January 18, 2006
A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activityJosephine L Meade, Erika A de Wynter, Peter Brett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2010
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trialHenrik Schmidt, Janet Brown, Ulrik Mouritzen, et al.
Pageof 5